| Customization: | Available |
|---|---|
| Powder: | Yes |
| Customized: | Non-Customized |
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product name | KPV |
| CAS No. | 67727-97-3 |
| MF | C16H30N4O4 |
| MW | 342.43 |
| Storage | -15°C |
2. Product Introduction
KPV is a tripeptide (i.e. 3 amino acids long) that makes up the C-terminal end of a larger naturally occurring melanocortin peptide hormone in your body known as alpha-melanocyte-stimulating hormone (α-MSH). Human body consists of various endogenous that are vital for the key body functions and overall development and wellbeing. One such group of hormones is called melanocyte stimulating hormones or melanotropins. These hormones are primarily responsible for hair and skin pigmentation, maintain optimal energy levels in the body, play key role in sexual activity and help protect against inflammation.Out of this class of melanotropin hormones, the most important hormones are alpha melanocyte stimulating hormones (a-MSH). a-MSH is an endogenous peptide hormone, composed of 13 amino acids, and is responsible for metabolic activities, sexual behavior and skin pigmentation.Over time, with the help of continuous research on a-MSH hormones, scientists were able to isolate a fragment of this protein hormone and identify its biological effects, especially its anti-inflammatory properties. This fragment is known as KPV peptide.
Continuous research between the two compounds have shown that while the peptide is an analogue of the hormone, there are certain differences between the two, which should be taken into consideration depending on the intended use:
a-MSH, the intact molecule, is the more potent molecule amongst the two. However, it has a serious drawback - excessive skin pigmentation - which is not seen in the case of the peptide. Furthermore, the peptide is remarkably easy to manufacture, thus making it less costly than the other compound.
a-MSH exerts its anti-inflammatory effects by binding with melanocortin receptors, including MC3 and MC4 receptors. The peptide does not bind to these MC3/4 receptors, but only to specific melanocortin receptors (such as MC1R). Thus, the mechanism of action of the two also differs.
Lastly, the peptide is more versatile in terms of administration - it can be easily administered via (either centrally or peripherally) through subcutaneous and intraperitoneal route, and can also be given orally. Latest research also shows that the peptide may be administered transdermally. This vast range of administrations suggest that the peptide will be more convenient for the patients to intake in the future.
|
Product name
|
CAS No.
|
|
β-Nicotinamide Mononucleotide (NMN)
|
1094-61-7
|
|
beta-Diphosphopyridine nucleotide (NAD)
|
53-84-9
|
|
Nicotinamide riboside chloride (NRC)
|
23111-00-4
|
|
Nicotinamide Ribose (NR)
|
1341-23-7
|
|
|
53-43
|
Extraction process:
){kind=link}